Researchers enrolled more than 4,000 adults from 16 countries in North America and Europe who had an implanted pacemaker, defibrillator or cardiac monitor that detected asymptomatic atrial fibrillation. This phase 4 clinical trial, called “Apixaban for the Reduction of Thrombo-Embolism in patients with device-detected Subclinical Atrial fibrillation trial (ARTESIA),” examined the risk-benefit considerations of treating asymptomatic atrial fibrillation. “So that’s a different risk-benefit consideration for prescribing anticoagulants.” “We have observed in previous research that the magnitude of stroke risk associated with short duration, asymptomatic, subclinical atrial fibrillation was lower than what was seen in people with longer-lasting symptomatic atrial fibrillation,” said study author Jeff Healey, M.D., M.S., cardiology division director and professor of medicine at McMaster University in Hamilton, Ontario, Canada. However, anti-clotting medications including apixaban cause an increased risk of major bleeding, including blood in stool or in urine, and/or trauma-related bleeding. Previous research has indicated that treatment with oral anti-clotting medications (also known as anticoagulants) may prevent up to two-thirds of strokes in people diagnosed with atrial fibrillation. Subclinical atrial fibrillation is brief, asymptomatic AFib that is detected by pacemakers, implantable defibrillators and cardiac monitors that record people’s heart rates continuously and detect these short bouts of irregular heartbeats. The medication was associated with major bleeding however, it was not life-threatening.Ītrial fibrillation, or AFib, is an irregular heartbeat that can lead to blood clots, stroke, heart failure or other heart-related complications. It can occur without symptoms or be so brief that it is difficult to detect. The full manuscript is also simultaneously published today in The New England Journal of Medicine. 11-13, in Philadelphia, is a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science. 12, 2023 - The anti-clotting medication apixaban reduced the rate of stroke and blood clots, among adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms compared to adults who took aspirin, according to late-breaking science presented today at the American Heart Association’s Scientific Sessions 2023. For many patients with brief, symptomless, subclinical atrial fibrillation, the benefits of apixaban likely outweigh risks, researcher said.Įmbargoed until 8:45 a.m. While the anti-clotting medication was linked with more bleeding, most bleeding did not result in any serious or permanent consequences.In a large study of adults with implanted heart devices that detected short, symptomless bouts of irregular heart rhythm, known as subclinical atrial fibrillation, those who took the anti-clotting medication apixaban were 37% less likely to have a stroke or blood clot compared to adults taking daily aspirin.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |